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   ’The subjective and urodynamic effects of an alpha adrenergic agent on voiding difflculty were
studied in 21 patients with benign prostatic hyperplasia and 6 patients with atonic type of neurogenic
vesical dysfunction． All patients were treated by oral administration of phenoxybenzamine 10 mg
daily for 14 days． The effectiveness was determined by the degree of relief of symptorns lrelated to
micturition， and the improvement in rate of residual urine， maximum fiow rate and urethral pressure
profile．
   In benign prostatic hyperplasia， the subjective and objective symptoms were Limproved in 76．ie／．
and 73．60／． of the patients， respectively． Particularly， the improvement in maximum flow rate was
statistically significant compared to the value before treatment． ln neurogenic vesical dysfunction，
the subjective and objective symptoms were improved in 500／o and 1000／， of the patients， respectively．
   From these results， phenoxybcnzamine was cQnsklered to be use婦in easing the vQid量ng ldifficulty
































































 ユ）尿流量測定法：DISA 2100 mictiometcrを用
いて最大尿流量率（maximum flow rate， ml／sec），排
尿量（voided volume），残尿量（volume of residual
urine）および残尿率（rate of residual urine）を計測
した．
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  9：腐心，と「言糊，Pぞ謝e（P・r酬）
   Pl／2ura：urethral pressure at 1／2 b
Fig． 1． Schematic pattern of the urtehral pressure
    profile in normal men． （CEted by Bates，












Table 1． Scoring for evaluation of subjective
     symptoms












































Tabie 2． Scoring for evaluation of
     objective signs
Objeetive signs Degrees Score
脚f1㎝鵬§ミ：1二1
           ナオ離一lll羅1二1
索
＞20 ％ increase than before treatment
＊ee
 ＞20 ％ decrease than before treatment
 他覚所見の効果判定は25例に施行された尿流量測定
および残尿量測定により最大尿流量率，残尿率の2項
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Table 3． Changes in subjective symptoms before and after the treatment period
Case
No．
Age Sex DiseaseNocturia Frequent
        urination
B  A B  A
1臨11t縮警。n
 B  A B  A
Sense of      丁otal  Effect























































































































































































































































































































































































BPH：Benign prostatic hyperplasia， NVD：Neurogenic vesical dyst’unction，
Table 4． Changes in urodynamic data before and after the treatment period











































































































































































































































Clhanges in objective signs before and
after the treatment period
Table 6．
931
Urethral pressure profile response to
a－adrenergic block
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Pura， max ： maximum urethral pressure
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Fig． 2． Urethral pressure profile response to a－adrenergic block． A， control；
    B， reduction of urethral pressure on administration of phenoxybenza－
    mine （Case 1）．
oo
悼
Table 7 Laboratory’@d a before and after treatment wfith POB in patients with lower urinary tracts obstruction
Case
No．
  Blood pressure
（、y、t。臨st。1，、）Puls篇e（lll・）
















GPT   A1－P


















































































469 426 7．2 9．6
380 416 7．3 9．4
439 443 4．0 5．9
37フ404 5．46．3
437 496 7．1 5．7
501 386 12．0 6．8
392 402 6．6 5．3









400 430 6．9 5．0 14．5 14．5
334 350 5．0 6．2 11．6 11．8
                   not done
                   not done
                   not’ done
                   not done
                   not done
                   not done
                   not done
                   not dene
481 515 5．2 5．2 16．0 16．7 29．2
                   not done
                   not done

















































 5 12 5．6 4．9
 8 19 5．1 4．5
13 16 3．9 6．3
 7 8 3．3 8．3
13 16 4．3 ・4．5
10 9 7．2 6．5
 4 8 6．8 6．1









21 30 4．2 4．0 not done
17 17 5．0 5．2 19，5 19．7
49 61 6，3 6，6 13．0 12．0
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Fig． 3． Urethral presg． ure profile response to a－adrenergic block． A， control；
    B， reduction of urethral pressure on administration of phenoxybenza－
    mine （Case 2）．
十 Urine leakage
A BN EM・
     ，
（感度100cmH。0）
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Fig． 4． Urethral pressure profiie respoBse to a－adrenergic block． A， control；
    B， reductien of urethral pressure on administration of phenoxybenza－
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十 Urine leakage
18 17 16 15 14 13 12 11 10 9
         十 Urine ieakage
BN
鷹1。。・m馴↓
18 17 16 15 14 13 12 11 10 9
Fig． 5． Urethral pressure profile response to a－
    adrenergic block． A， control； B， reduction
    of urethral pressure on administration of


















































        15 14 13 12 11 10
Fig． 6． Urethral pressure profile response to a－adrenergic block． A， control；
    B， reduction of urethral pressure on admlnistration of phenoxybenza－
    mine （Case 23）．
                     北野・ほか：下部尿路閉塞性疾，患、・尿流動態
                             BN ．“ Ur」ne leakage
           A，感度1。。、mH、。）↓
                  18 17 16 15 14 13． 12 11109 8 7 6 5 4
                                         十 Urine leakage
           B BN
               （pt．． ff」clcocmH 20） lr ，
                                                        一一一N’“・一M．．．
                             15 14 13 12 ll 10
Fig． 7． Urethral ptessure profile response to cr－adrenergic block． A， control J B， reduction
     of urethral pressure on administration of phenoxybenzamine （Case 24） ．
                                             i Urine leakage
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                    （感度100c面H20）
                              17 16 IS 14 13 12
                                            “ Urine leakage
                  B BN
                                ，
                    （感度100cmH20）
                             17 16 15 14 13 12
 Fig． 8． Ureth．ral pressure profile respense to cr－adrenergic block． A， control；B， reduction
         of urehtral pressure on administration of phenoxybenzamine （Case 25）．
                      BN ．． EM
A、感度1。。一，、。，↓      ↓
           18 17 16 15 14 13 12
                                            EM
                      BN
                      十／x 十
       （感度100cmH20）B
                      15 1413 12
Fig．9． Urethral pressure profile res－ponse to cr－adrenergic block． A， contro13 B， increase
        of urethral pressure on administration of phenoxybenzamine （Case 26）．
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求h㌧〔ｭ  碑轄響，講
難 麟纏
   麟鐡簸 鱗i灘滝
          亭
欝鵬麟 藷識謙麟解鵠綴灘鵬
Fig． 10． Schematic representation of cholinergic
     and adrenergic receptors in the lower uri－
     nary tract． Note the distribution of al－
     pha adrenergic receptors in trigone， ure－
     thral smooth muscle and external sphinc－
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